Overview

Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)

Status:
RECRUITING
Trial end date:
2026-01-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-2828. The study will also measure what happens to MK-2828 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC